Melanoma: What Do All the Mutations Mean?

被引：134

作者：

Davis, Elizabeth J. ^{[1
]}

Johnson, Douglas B. ^{[1
]}

Sosman, Jeffrey A. ^{[2
]}

Chandra, Sunandana ^{[2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA

[2] Northwestern Univ, Dept Med, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

CANCER | 2018年 / 124卷 / 17期

基金：

美国国家卫生研究院;

关键词：

BRAF; cyclin-dependent kinase inhibitor 2A (CDKN2A); KIT; melanoma; mutation; NRAS; programmed cell death protein 1 (PD-1); PROGRESSION-FREE SURVIVAL; METASTATIC MELANOMA; BRAF MUTATIONS; OPEN-LABEL; ACQUIRED-RESISTANCE; DRIVER MUTATIONS; CTLA-4; BLOCKADE; NRAS MUTATIONS; PD-1; PHASE-II;

D O I：

10.1002/cncr.31345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both "driver" and "passenger" genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma. (C) 2018 American Cancer Society.

引用

页码：3490 / 3499

页数：10

共 94 条

[41] Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies [J].

Johnson, Douglas B. ;

Lovly, Christine M. ;

Flavin, Marisa ;

Panageas, Katherine S. ;

Ayers, Gregory D. ;

Zhao, Zhiguo ;

Iams, Wade T. ;

Colgan, Marta ;

DeNoble, Sarah ;

Terry, Charles R. ;

Berry, Elizabeth G. ;

Iafrate, A. John ;

Sullivan, Ryan J. ;

Carvajal, Richard D. ;

Sosman, Jeffrey A. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) :288-295

[42] BRAF inhibitor activity in V600R metastatic melanoma [J].

Klein, Oliver ;

Clements, Arthur ;

Menzies, Alexander M. ;

O'Toole, Sandra ;

Kefford, Richard F. ;

Long, Georgina V. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (05) :1073-1079

[43] Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas [J].

Krauthammer, Michael ;

Kong, Yong ;

Bacchiocchi, Antonella ;

Evans, Perry ;

Pornputtapong, Natapol ;

Wu, Cen ;

McCusker, James P. ;

Ma, Shuangge ;

Cheng, Elaine ;

Straub, Robert ;

Serin, Merdan ;

Bosenberg, Marcus ;

Ariyan, Stephan ;

Narayan, Deepak ;

Sznol, Mario ;

Kluger, Harriet M. ;

Mane, Shrikant ;

Schlessinger, Joseph ;

Lifton, Richard P. ;

Halaban, Ruth .

NATURE GENETICS, 2015, 47 (09) :996-+

[44] Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma [J].

Krauthammer, Michael ;

Kong, Yong ;

Ha, Byung Hak ;

Evans, Perry ;

Bacchiocchi, Antonella ;

McCusker, James P. ;

Cheng, Elaine ;

Davis, Matthew J. ;

Goh, Gerald ;

Choi, Murim ;

Ariyan, Stephan ;

Narayan, Deepak ;

Dutton-Regester, Ken ;

Capatana, Ana ;

Holman, Edna C. ;

Bosenberg, Marcus ;

Sznol, Mario ;

Kluger, Harriet M. ;

Brash, Douglas E. ;

Stern, David F. ;

Materin, Miguel A. ;

Lo, Roger S. ;

Mane, Shrikant ;

Ma, Shuangge ;

Kidd, Kenneth K. ;

Hayward, Nicholas K. ;

Lifton, Richard P. ;

Schlessinger, Joseph ;

Boggon, Titus J. ;

Halaban, Ruth .

NATURE GENETICS, 2012, 44 (09) :1006-+

[45] Initial sequencing and analysis of the human genome [J].

Lander, ES ;

Int Human Genome Sequencing Consortium ;

Linton, LM ;

Birren, B ;

Nusbaum, C ;

Zody, MC ;

Baldwin, J ;

Devon, K ;

Dewar, K ;

Doyle, M ;

FitzHugh, W ;

Funke, R ;

Gage, D ;

Harris, K ;

Heaford, A ;

Howland, J ;

Kann, L ;

Lehoczky, J ;

LeVine, R ;

McEwan, P ;

McKernan, K ;

Meldrim, J ;

Mesirov, JP ;

Miranda, C ;

Morris, W ;

Naylor, J ;

Raymond, C ;

Rosetti, M ;

Santos, R ;

Sheridan, A ;

Sougnez, C ;

Stange-Thomann, N ;

Stojanovic, N ;

Subramanian, A ;

Wyman, D ;

Rogers, J ;

Sulston, J ;

Ainscough, R ;

Beck, S ;

Bentley, D ;

Burton, J ;

Clee, C ;

Carter, N ;

Coulson, A ;

Deadman, R ;

Deloukas, P ;

Dunham, A ;

Dunham, I ;

Durbin, R ;

French, L .

NATURE, 2001, 409 (6822) :860-921

[46] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [J].

Le, D. T. ;

Uram, J. N. ;

Wang, H. ;

Bartlett, B. R. ;

Kemberling, H. ;

Eyring, A. D. ;

Skora, A. D. ;

Luber, B. S. ;

Azad, N. S. ;

Laheru, D. ;

Biedrzycki, B. ;

Donehower, R. C. ;

Zaheer, A. ;

Fisher, G. A. ;

Crocenzi, T. S. ;

Lee, J. J. ;

Duffy, S. M. ;

Goldberg, R. M. ;

de la Chapelle, A. ;

Koshiji, M. ;

Bhaijee, F. ;

Huebner, T. ;

Hruban, R. H. ;

Wood, L. D. ;

Cuka, N. ;

Pardoll, D. M. ;

Papadopoulos, N. ;

Kinzler, K. W. ;

Zhou, S. ;

Cornish, T. C. ;

Taube, J. M. ;

Anders, R. A. ;

Eshleman, J. R. ;

Vogelstein, B. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2509-2520

[47] Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J].

Le, Dung T. ;

Durham, Jennifer N. ;

Smith, Kellie N. ;

Wang, Hao ;

Bartlett, Bjarne R. ;

Aulakh, Laveet K. ;

Lu, Steve ;

Kemberling, Holly ;

Wilt, Cara ;

Luber, Brandon S. ;

Wong, Fay ;

Azad, Nilofer S. ;

Rucki, Agnieszka A. ;

Laheru, Dan ;

Donehower, Ross ;

Zaheer, Atif ;

Fisher, George A. ;

Crocenzi, Todd S. ;

Lee, James J. ;

Greten, Tim F. ;

Duffy, Austin G. ;

Ciombor, Kristen K. ;

Eyring, Aleksandra D. ;

Lam, Bao H. ;

Joe, Andrew ;

Kang, S. Peter ;

Holdhoff, Matthias ;

Danilova, Ludmila ;

Cope, Leslie ;

Meyer, Christian ;

Zhou, Shibin ;

Goldberg, Richard M. ;

Armstrong, Deborah K. ;

Bever, Katherine M. ;

Fader, Amanda N. ;

Taube, Janis ;

Housseau, Franck ;

Spetzler, David ;

Xiao, Nianqing ;

Pardoll, Drew M. ;

Papadopoulos, Nickolas ;

Kinzler, Kenneth W. ;

Eshleman, James R. ;

Vogelstein, Bert ;

Anders, Robert A. ;

Diaz, Luis A., Jr. .

SCIENCE, 2017, 357 (6349) :409-413

[48] BRAF Mutations and KIT Aberrations and Their Clinicopathological Correlation in 202 Korean Melanomas [J].

Lin, Sun A. ;

Chun, Seung Min ;

Choi, Yoo-Duk ;

Kweon, Sun-Seog ;

Jung, Sung Taek ;

Shim, Hyun Jeong ;

Yun, Sook Jung .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (02) :579-582

[49] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma [J].

Long, G. V. ;

Hauschild, A. ;

Santinami, M. ;

Atkinson, V. ;

Mandala, M. ;

Chiarion-Sileni, V. ;

Larkin, J. ;

Nyakas, M. ;

Dutriaux, C. ;

Haydon, A. ;

Robert, C. ;

Mortier, L. ;

Schachter, J. ;

Schadendorf, D. ;

Lesimple, T. ;

Plummer, R. ;

Ji, R. ;

Zhang, P. ;

Mookerjee, B. ;

Legos, J. ;

Kefford, R. ;

Dummer, R. ;

Kirkwood, J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1813-1823

[50] Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials [J].

Long, Georgina V. ;

Grob, Jean-Jacques ;

Nathan, Paul ;

Ribas, Antoni ;

Robert, Caroline ;

Schadendorf, Dirk ;

Lane, Stephen R. ;

Mak, Carmen ;

Legenne, Philippe ;

Flaherty, Keith T. ;

Davies, Michael A. .

LANCET ONCOLOGY, 2016, 17 (12) :1743-1754

← 1 2 3 4 5 6 7 8 9 10 →